Form 4: Adverum Biotechnologies Acquired by Eli Lilly

Adverum Biotechnologies, Inc. became a wholly-owned subsidiary of Eli Lilly and Company following a tender offer and merger, with shareholders receiving cash and contingent value rights.

Summary

• Adverum Biotechnologies, Inc. was acquired by Eli Lilly and Company through its direct wholly-owned subsidiary, Flying Tigers Acquisition Corporation.
• The merger became effective on December 9, 2025, at which point Adverum Biotechnologies, Inc. continued as the surviving entity and a wholly-owned subsidiary of Eli Lilly and Company.
• Tendering stockholders received $3.56 per share in cash (Cash Consideration) and one non-tradable contingent value right (CVR) for each share.
• Each CVR represents the contractual right to receive up to two contingent cash payments, totaling up to an aggregate of $8.91 per CVR, upon the achievement of specified milestones.
• Stock options with an exercise price equal to or greater than the Cash Consideration ($3.56) were fully vested prior to the merger and then cancelled for no consideration.
• Stock options with an exercise price less than the Cash Consideration ($3.56) were automatically cancelled, with holders receiving a cash amount equal to the product of (Cash Consideration exercise price) multiplied by the number of shares, plus one CVR for each share subject to the option.

Sentiment

Score: 7

Explanation: The acquisition provides a definitive cash value for shareholders and potential upside through CVRs, representing a successful outcome for the company's lifecycle. However, the cancellation of out-of-the-money options for no consideration is a negative for some option holders.

Positives

• Adverum shareholders received a definitive cash payment of $3.56 per share.
• Shareholders also received Contingent Value Rights (CVRs), offering potential additional payments of up to $8.91 per CVR based on the achievement of specified milestones.
• The acquisition by a major pharmaceutical company like Eli Lilly provides a clear and structured exit for Adverum shareholders and validates the company's assets.

Negatives

• Stock options with an exercise price equal to or greater than $3.56 were cancelled for no consideration, resulting in no value for those option holders.
• Adverum Biotechnologies, Inc. ceases to be an independent publicly traded entity, removing its stock from public markets.
• The Contingent Value Rights (CVRs) are non-tradable, limiting liquidity and the ability for holders to realize their value before milestone achievement.

Risks

• The contingent cash payments from CVRs are not guaranteed and are dependent on the achievement of specified milestones, meaning the full $8.91 per CVR may not be realized.
• The non-tradable nature of the CVRs means holders cannot sell them on the open market, restricting their ability to monetize the contingent value.

Future Outlook

Adverum Biotechnologies, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company, indicating its future operations will be integrated within Eli Lilly's broader strategic framework. The future value for former Adverum shareholders holding CVRs is contingent upon the successful achievement of specified milestones.

Industry Context

This acquisition reflects a continuing trend in the biotechnology and pharmaceutical sectors where larger companies acquire smaller biotech firms to expand their pipelines, gain access to new technologies, or consolidate market positions. The use of CVRs is a common strategy in such deals to manage risk and align incentives for future product development.

Comparison to Industry Standards

• The structure of the acquisition, involving an upfront cash payment combined with contingent value rights (CVRs), is a common mechanism in the biotechnology industry for deals where the acquired assets have significant future development milestones.
• This approach is comparable to other recent biotech acquisitions where the acquiring company seeks to mitigate upfront valuation risk while providing potential upside to the selling shareholders based on future performance, such as the acquisition of Reata Pharmaceuticals by Biogen or the acquisition of Prometheus Biosciences by Merck.

Stakeholder Impact

• Shareholders: Received cash and CVRs in exchange for their Adverum shares, losing their equity in an independent public company.
• Employees: Adverum employees are now part of Eli Lilly and Company, which may lead to changes in roles, benefits, and corporate culture.
• Management: Former Adverum management roles will likely be integrated or restructured within Eli Lilly's organizational framework.
• Creditors: Adverum's obligations are now effectively backed by Eli Lilly and Company, potentially enhancing creditworthiness.

Next Steps

• Achievement of specified milestones for the contingent cash payments associated with the CVRs.
• Integration of Adverum Biotechnologies' operations and assets into Eli Lilly and Company.

Key Dates

Keywords

Adverum Biotechnologies, Eli Lilly, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Option, ADVM, Biotechnology, Pharmaceuticals